Last €64.69 EUR
Change Today -0.76 / -1.16%
Volume 425.0
BVF On Other Exchanges
Symbol
Exchange
New York
Frankfurt
Toronto
As of 10:47 AM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (BVF) Snapshot

Open
€64.09
Previous Close
€65.45
Day High
€64.69
Day Low
€63.78
52 Week High
05/28/13 - €73.80
52 Week Low
06/29/12 - €34.70
Market Cap
--
Average Volume 10 Days
160.7
EPS TTM
--
Shares Outstanding
0.0
EX-Date
11/10/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (BVF)

valeant pharmaceuticals inte (BVF) Latest News

More News

valeant pharmaceuticals inte (BVF) Related Businessweek News

View More BusinessWeek News

valeant pharmaceuticals inte (BVF) Details

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. It offers dermatology products, such as Zovirax Ointment, Xerese, Retin-A Micro, Elidel, Carac, Acanya gel, Sculptra and Sculptra Aesthetic, Atralin, Solodyn, Zyclara, Ziana, Vanos, Restylane family of products, and Dysport; over-the-counter (OTC) products, including CeraVe and AcneFree; dentistry products, such as Arestin and Teeth Whitening System; ophthalmology products, including Timoptic, Timoptic, Macugen, and Visudyne; and neurology and other products, such as Wellbutrin XL and Xenazine in the United States. The company also provides pharmaceutical products, including Tiazac XC, Wellbutrin XL, Zovirax, Benzaclin, and Penlac; and Cold-FX, an OTC product in Canada, as well as Duromine/Metermine, Difflam, Duro-Tuss, and Rikodeine in Australia. In addition, it offers a range of treatments, including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products, and diabetic therapies, as well as a range of various OTC products in Europe; and products for a range of therapeutic classes, including vitamin deficiency, antibacterials, and dermatology in Mexico and Brazil. Further, the company provides Duromine, Andolex, and Pholtex products in South Africa; and Difflam, Duro-Tuss, Tambocor, and Norgesic in Asia. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

7,000 Employees
Last Reported Date: 02/28/13
Founded in 1983

valeant pharmaceuticals inte (BVF) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $1.7M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0M
Executive Vice President, Group Chairman of T...
Total Annual Compensation: $281.3K
Executive Vice President of Corporate Busines...
Total Annual Compensation: $550.0K
Chief Human Capital Officer and Executive Vic...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2012.

valeant pharmaceuticals inte (BVF) Key Developments

Valeant Seeks Acquisitions

Valeant Pharmaceuticals International, Inc. (TSX:VRX) seeks acquisitions. Valeant Pharmaceuticals International Inc. has filed a preliminary prospectus to raise gross proceeds of approximately $1.75 billion. Valeant plans to use the net proceeds with debt financing, to fund the merger of Bausch + Lomb Holdings Incorporated and repayment or retirement of Bausch + Lomb's outstanding debt. If the Merger were not to close for any reason, the proceeds will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions.

Valeant Pulls Back From Galenika Bidding Process

Valeant Pharmaceuticals International, Inc. (TSX:VRX) has pulled back from its possible bid for Galenika a.d. from the Serbian government in the wake of its $8.7 billion purchase of Bausch & Lomb Holdings Incorporated. Valeant Pharmaceuticals’ said that the acquisition of Bausch & Lomb as the hostility of local unions towards the purchase of Galenika Pharmaceuticals it had decided not to follow up its letter of intent relating to Galenika's privatization. "Major reasons for this decision are (the) recently announced agreement to acquire Bausch & Lomb and publicly expressed hostile attitude of Galenika, trade unions and employees," Mirko Bogdanov, Head of the European unit of Valeant Pharmaceuticals North America said in a letter to Serbian Finance Minister, Mladjan Dinkic. Reuters reported that the officials from the Serbian Finance Ministry were not immediately available for comment.

Serbia Extends Galenika Sale

Serbian government extended for another two weeks a deadline for bids for its Galenika a.d. Valeant Pharmaceuticals International, Inc. (TSX:VRX) is the sole candidate so far. The finance ministry said the new deadline was June 14, 2013 the fourth extension since offers were first invited on January 14, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BVF:GR €64.69 EUR -0.76

BVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis Inc $123.93 USD -1.74
Allergan Inc/United States $99.51 USD -1.98
Forest Laboratories Inc $41.96 USD +0.385
Shire PLC 2,086 GBp -1.00
Sun Pharmaceutical Industries Ltd 961.25 INR -10.65
View Industry Companies
 

Industry Analysis

BVF

Industry Average

Valuation BVF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book 7.3x
Price/Cash Flow 33.0x
TEV/Sales 4.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.